Gentex (GNTX) Q3 2025 earnings summary

Executive summary

• Consolidated net sales reached $655.2 million in Q3 2025, up 8% year-over-year, driven by the VOXX acquisition, while core revenue declined 6% to $570.3 million.

• Net income attributable to shareholders was $101.0 million, down from $122.5 million, mainly due to a prior-year one-time gain from the VOXX investment.

• Earnings per diluted share were $0.46, compared to $0.53 last year.

• 1.0 million shares repurchased for $28.3 million during the quarter; 9.8 million shares repurchased year-to-date.

• Major acquisitions included VOXX (April 2025) and BioConnect (July 2025), expanding product lines and market reach.

Financial highlights

• Gross margin improved to 34.4% from 33.5% year-over-year, with core Gentex margin up 140 basis points to 34.9%.

• Operating expenses increased to $102.8 million, mainly from the VOXX acquisition.

• Income from operations was $122.3 million, down from $125.7 million year-over-year.

• Cash and equivalents were $178.6 million, down from $233.3 million at year-end, reflecting the VOXX acquisition and share repurchases.

• Operating cash flow for Q3 was $146.9 million, up from $84.7 million year-over-year.

Outlook and guidance

• 2025 consolidated revenue guidance is $2.5–$2.6 billion, with gross margin expected at 33.5%–34%.

• Operating expenses (excluding severance) forecasted at $380–$390 million; CapEx at $115–$125 million.

• Effective tax rate projected at 16%–16.5%.

• Stand-alone guidance: Gentex revenue $2.14–$2.15 billion, China $135–$145 million, VOXX $250–$270 million.

• Global light vehicle production for Q4 2025 expected to decline 4% year-over-year; full-year 2025 production in primary markets to fall 1%–2%.